top of page

BIO Ventures for Global Health

BIO Ventures for Global Health (BVGH) is a non-profit organization based in Seattle, USA that forges and manages multinational public-private partnerships across infectious and non-communicable diseases to build clinical trial and early-stage research and development (R&D) capacity; catalyze innovative R&D; and expand access to quality healthcare in low- and middle-income countries (LMICs)—with a focus on Africa.

 

Founded in 2003, BVGH brings decades of scientific training, project management expertise, and biotechnology and pharmaceutical industry experience to partnership development and execution. BVGH’s programs include the African Access Initiative (AAI), African Consortium for Cancer Clinical Trials (AC³T), and Global Innovation Alliance (GIA). GIA builds upon BVGH’s experience and successes in co-leading initiatives including the Pool for Open Innovation Against Neglected Tropical Diseases (POINT) and WIPO Re:Search.

BVGH.png

Capabilities and Experience

​

Clinical Trial Capacity Building

  • Clinical trial and regulatory training programs to address skill gaps.

  • Mentored grant programs to support clinical studies designed and led by LMIC investigators.

  • Online platform showcasing LMIC sites’ clinical trial expertise and facilities.

  • Alliance management support for mutually beneficial clinical trial partnerships between LMIC investigators and global collaborators.

 

Infectious Disease R&D Stakeholder Engagement, Network Development, Partnering and Alliance Management, Capacity Strengthening

  • Cross-sector expert network spanning 200+ organizations in 50+ countries.

  • 185+ R&D collaborations (40% engaging LMIC partners; 63% involving sharing of industry intellectual property).

  • 100+ months of fellowships and virtual training for 26 researchers (46% women) in 12 LMICs.

 

With BVGH’s support, LMIC scientists have advanced their infectious disease R&D programs—through generation of critical data; receipt of competitive grants; peer-reviewed publications; and international presentations—while earning career promotions and other professional recognition. 

 

Infectious Disease Landscape Analyses (Drug, Diagnostic, Vaccine Pipelines)

  • Neglected tropical diseases, for the Bill & Melinda Gates Foundation.

  • Malaria, tuberculosis, and Ebola virus disease, for the World Health Organization.

  • 25 neglected diseases, under the rubric of the Global Health Primer.

 

Communications

Publications and presentations reaching leaders and decision-makers on six continents, including:

  • Biotechnology and pharmaceutical companies.

  • Funders.

  • Governments.

  • Mainstream media.

  • Non-governmental organizations.

  • Researchers.

  • United Nations agencies.

 

CTCAN Key Roles and Contributions

Network Development

  • Provide validated clinical trial site profiling tools—developed through AC3T and GIA—to inform and facilitate site mapping and capabilities assessments.  

  • Advise on best practices and lessons learned for clinical trial site engagement.

  • Share (with consent) capabilities profiles of African infectious disease organizations in BVGH’s network.

 

Capacity Development

  • Organize and implement training programs for clinical sites, laboratories, and regulatory agencies to advance clinical trial preparedness.

  • Share training materials across the CTCAN network.

 

Communications

  • Develop communications materials (e.g., blog posts, news articles) showcasing CTCAN activities and results.

  • Disseminate BVGH-developed and partner-developed communications through BVGH’s web, email, and social media platforms (reaching thousands of subscribers and followers worldwide) to raise CTCAN’s visibility.

bottom of page